172 related articles for article (PubMed ID: 16900372)
1. Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells.
Kurebayashi J; Nukatsuka M; Nagase H; Nomura T; Hirono M; Yamamoto Y; Sugimoto Y; Oka T; Sonoo H
Cancer Chemother Pharmacol; 2007 Mar; 59(4):515-25. PubMed ID: 16900372
[TBL] [Abstract][Full Text] [Related]
2. Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer.
Kurebayashi J; Nukatsuka M; Sonoo H; Uchida J; Kiniwa M
Cancer Chemother Pharmacol; 2010 Jan; 65(2):219-25. PubMed ID: 19455332
[TBL] [Abstract][Full Text] [Related]
3. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
4. Chemoendocrine therapy in DMBA-induced rat mammary carcinoma.
Morimoto T; Yamamoto H; Komaki K; Konishi N; Tanaka T; Yamakawa T; Mori T; Sasa M; Monden Y
Tokushima J Exp Med; 1990 Dec; 37(3-4):59-68. PubMed ID: 2128782
[TBL] [Abstract][Full Text] [Related]
5. Sequential combination chemotherapy in human breast cancer: a basis for increased antineoplastic activity and bone marrow protection.
Davis JH; Desoto JA; Fryar EB; Southerland WM; Bowen D
Cell Mol Biol (Noisy-le-grand); 2007 May; 53(3):18-26. PubMed ID: 17531145
[TBL] [Abstract][Full Text] [Related]
6. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer.
Pierce LJ; Hutchins LF; Green SR; Lew DL; Gralow JR; Livingston RB; Osborne CK; Albain KS
J Clin Oncol; 2005 Jan; 23(1):24-9. PubMed ID: 15545669
[TBL] [Abstract][Full Text] [Related]
7. Influence of different combinations of tamoxifen and toremifene on estrogen receptor-positive breast cancer cell lines.
Coradini D; Biffi A; Cappelletti V; Di Fronzo G
Cancer Detect Prev; 1995; 19(4):348-54. PubMed ID: 7553677
[TBL] [Abstract][Full Text] [Related]
8. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines.
Vendrell JA; Bieche I; Desmetz C; Badia E; Tozlu S; Nguyen C; Nicolas JC; Lidereau R; Cohen PA
Endocr Relat Cancer; 2005 Mar; 12(1):75-92. PubMed ID: 15788640
[TBL] [Abstract][Full Text] [Related]
9. Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells.
Burke PJ; Kalet BT; Koch TH
J Med Chem; 2004 Dec; 47(26):6509-18. PubMed ID: 15588086
[TBL] [Abstract][Full Text] [Related]
10. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
12. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
Guo Y; Mazar AP; Lebrun JJ; Rabbani SA
Cancer Res; 2002 Aug; 62(16):4678-84. PubMed ID: 12183425
[TBL] [Abstract][Full Text] [Related]
13. Dietary flaxseed interaction with tamoxifen induced tumor regression in athymic mice with MCF-7 xenografts by downregulating the expression of estrogen related gene products and signal transduction pathways.
Chen J; Power KA; Mann J; Cheng A; Thompson LU
Nutr Cancer; 2007; 58(2):162-70. PubMed ID: 17640162
[TBL] [Abstract][Full Text] [Related]
14. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
15. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
16. Effects of short term treatment with pentagastrin, proglumide, tamoxifen given separately or together with 5-fluorouracil on the growth in the murine transplantable Colon 38 cancer.
Mełeń-Mucha G
Neoplasma; 2001; 48(2):133-8. PubMed ID: 11478694
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen circumvents the multidrug resistance in fresh human gastrointestinal cancer cells.
Hotta T; Tanimura H; Yamaue H; Iwahashi M; Tani M; Tsunoda T; Tamai M; Noguchi K; Mizobata S; Arii K; Terasawa H
J Surg Res; 1996 Nov; 66(1):31-5. PubMed ID: 8954828
[TBL] [Abstract][Full Text] [Related]
19. Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin.
McClay EF; Jones JA; Winski PJ; Albright KD; Christen RD; Howell SB
Cancer Res; 1996 Sep; 56(17):3993-7. PubMed ID: 8752169
[TBL] [Abstract][Full Text] [Related]
20. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow.
Das JR; Fryar-Tita EB; Zhou Y; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(6B):3791-9. PubMed ID: 18225534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
